Drug-coated stent looks promising in trial:
This article was originally published in Clinica
Executive Summary
Biocompatibles International's coronary stent coated with a drug made by Abbott Laboratories looks to be a promising way of preventing restenosis, according to early data from a preclinical trial. The US study involving pigs show that the drug-coated devices lead to a 43% reduction in new tissue growth, with related improvement in internal vessel size and no significant injury or inflammation within the treated artery. Biocompatibles of Farnham, UK, is investigating the use of a number of anti-restenosis pharmaceuticals for use on its stent.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.